Long-term Trends and Influencing Factors of Glomerular Filtration Rate

Hao- Huan Hu1, Chin-Wen Hsieh1, Yu-Kuei Liao2, Chao-Hsien Lee3, Chia-Hsin Lai4, Szu-Mei Hsiao5, Pi-Li Lin5, Tsan Yang3\*

1Pingtung Christian Hospital, the Division of Nephrology, Pingtung County, Taiwan.

2Pingtung Christian Hospital, Nursing Department, Pingtung County, Taiwan.

3Department of Health Business Administration, Meiho University, Pingtung County, Taiwan.

4Department of Physical Therapy, Tzu Hui Institute of Technology, Taiwan.

5Department of Nursing, Meiho University, Pingtung County, Taiwan.

Corresponding author: Tsan Yang, Associate Professor

Department of Health Business Administration, Meiho University, Pingtung County, Taiwan.

Tel: +886-**8-7799821 ext 8334**

E-mail: x00002115@meiho.edu.tw

**Abstract**

**Background:** Chronic kidney disease (CKD) is one of the predominant epidemic diseases in the world. The high incidence rate and prevalence of CKD in Taiwan has become a severe burden for medical resources. CKD has recently become an important disease that all nations aim to prevent and control.

**Purpose:** This study assessed CKD in Pingtung, Taiwan as indicated by the annual changes glomerular filtration rate (GFR) and risk factors of estimated glomerular filtration rate (eGFR).

**Methods:** This study utilized longitudinal data analysis to examine the 2011-2013 medical checkup results for adult at a Pingtung hospital. The participants' general information, physical examination results, and blood test results were analyzed. eGFR was calculated via the abbreviated modification of diet in renal disease (aMDRD) formula and used to determine eFGR stages based on the 2002 Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines.

**Results:** Data from a total of 9,702 participants were analyzed in this study. The results indicated that declines in eGFR in stages 1-5 significantly increased with age. Participants who were male and those aged ≥65 years showed a more rapid decline in eGFR than female and <65-year-old participants. This study indicated that in Pingtung, from 2011 to 2013, male, aged ≧65 years and those who have metabolic syndrome and its components are abnormal have lower eGFR. Multiple linear regression analysis was applied to examine the risk factors influencing eGFR. The results showed lower eGFR in males, participants aged 65 and over, participants with metabolic syndrome, blood pressure, waist circumference, and triglyceride level abnormalities.

**Conclusion:** The results of this study indicated that in Pingtung, from 2011 to 2013, males, participants aged 65 and over, and participants with abnormal components of metabolic syndrome had lower eGFRs. Predictors of eGFR decline included male gender, age of 65 years and over, metabolic syndrome, and abnormal blood pressure, waist circumference, and triglyceride levels.

**Keywords:** Chronic kidney disease, aMDRD formula, glomerular filtration rate, metabolic syndrome

**Introduction**

The improvements in medical care and living standards and changes in diet and lifestyle have resulted in growing incidence and prevalence rates for chronic kidney disease (CKD) and end stage renal disease (ESRD). Mortality rates in people with CKD have increased [1] and so have medical care burden and expenditures. Therefore, CKD prevention and cure has become an important issue in public health worldwide. Kidney diseases, such as nephritis, nephrotic syndrome, and nephropathy, were the tenth leading cause of death in Taiwan in 2012 and have been among the top ten leading causes of death in Taiwan for over a decade [2]. Due to the improvements in health care in Taiwan, many older adults and those with chronic diseases do not die from cardiovascular complications during the beginning stages of CKD. However, survivors suffer from impaired kidney function and require dialysis or transplantation. The number of dialysis patients increases by approximately 6% each year, indicating a decline in health in Taiwan and increasing annual insurance expenditures to NT$30 billion [3].

The high incidence and prevalence of ESRD is an important issue in Taiwan. However, the prevalence of early stage CKD is even higher. The progression of early stage CKD into ESRD is associated with an increased mortality for those with cardiovascular diseases and imposes a heavy psychological and economic burden on individuals, families, and society. As such, countries worldwide have made efforts to prevent and cure this disease. Serum creatinine has been replaced by estimated glomerular filtration rate (eGFR) in the early diagnosis of CKD, which has greatly affected detection of early stage CKD in recent years, and the clinical diagnosis and treatment following the new Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines have been widely applied [4]. CKD is highly prevalent in southern Taiwan. However, the annual changes in CKD prevalence based on eGFR and eGFR risk factors have been rarely studied. Thus, this study examined the annual changes in eGFR-based CKD prevalence rates and identified risk factors for a lower eGFR.

**Methods**

**Study design**

 This study utilized longitudinal data analysis to examine the medical health check results for adults at a hospital in Pingtung, Taiwan from 2011 to 2013. Participants' general information and physical examination and blood test results were analyzed.

**Participants**

The participants in this study were adults who had undergone a health check (or integrated screening). After excluding those who did not finish the physical examination or biochemical blood tests, the sample included a total of 9,702 participants.

**Research instruments**

**Physical examination**

**(1)** Waist circumference (WC): WC was measured to the nearest 0.1cm on bare skin midway between the lower rib margin and the iliac crest at the end of gentle expiration.

**(2)** Blood pressure (BP): Trained nurses measured the systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the left arm of seated participants twice according to a standardized protocol. A third BP measurement was made if the first two BP readings differed by more than 10 mm Hg. The average of the two closest readings was calculated to determine the reported BP for each participant.

 **(3)** Biochemical determinations: Participants were required to fast for a minimum of 10 hours prior to the biochemical blood test which measured triglycerides, high-density lipoprotein cholesterol (HDL-C), and plasma glucose levels.

**Definition of terms**

Definition of eGFR: In the present study, the GFR was estimated using the Modification of Diet in Renal Disease (MDRD), and CKD was grouped into 5 stages based on the categorization of CKD by the National Kidney Foundation, Inc.: a participant whose eGFR ≥90 ml/min/1.73m2 with proteinuria was in stage 1; those with eGFR ≥60-89 ml/min/1.73m2 with proteinuria were in stage 2; those with eGFR ≥30-59 ml/min/1.73m2 were in stage 3; those with eGFR ≥15- 29ml/min/1.73m2 were in stage 4; those with eGFR <15ml/min/1.73m2 were in stage 5.

Metabolic syndrome: Metabolic syndrome status was defined according to the criteria set by the Health Promotion Administration, Ministry of Health and Welfare in 2007. Any three of the following five criteria were grounds for identifying metabolic syndrome: (1) abdominal obesity: waist circumference (WC) ≥90 cm in men and ≥80 cm in women; (2) raised triglycerides (TG): ≥150 mg/dL; (3) reduced HDL-C: HDL-C *<*40 mg/dL in men and *<*50 mg/dL in women; (4) hypertension: blood pressure of at least 130/85mmHg or taking antihypertensive medication; and (5) raised fasting plasma glucose (FPG) ≥100 mg/dL and/or taking anti-glycemic medication.

**Ethics**

This study analyzed secondary numerical data from participants' health checks and integrated screening results. Before using the data, consent was obtained from the hospital. During data collection, all the data were anonymized in order to adhere to ethical principles. This study was approved by the institutional review board before data collection.

**Statistical analyses**

The present study analyzed data using SPSS 17.0 (SPSS for Windows release 17.0), with a significance level of α= .05. Inferential statistics applied the Chi-square, independent t test and multiple linear regression model for analytics.

**Results**

The data from 9,702 participants were analyzed in this study. The analysis results for the changes in GFRs over three years in Table 1 show a significant annual increase in the number of participants with eGFR<60 ml/min/1.73m2. An eGFR<60 ml/min/1.73m2 was more prevalent in males and aged 65 and over compared to females and under 65 years (Table 2). Participants with abnormal metabolic syndrome and its components were found to have significantly lower eGRF than those without such abnormalities. Similar conclusions can be drawn from Table 3. The yearly results in Table 4 show significantly lower eGRFs were observed in males, aged 65 and over, and participants with abnormal metabolic syndrome and its components. Table 5 shows risk factors influencing eGFR. The results indicated that lower eGFR was related to male gender, age ≥65 years, metabolic syndrome, and abnormal BP, WC, and triglyceride levels.

**Discussion**

CKD is not easily detected in its early stages. CKD severity and stage can be determined mainly based on GFR and renal injuries. A lower GFR is associated with a higher mortality rate, prevalence of cardiovascular diseases, and hospitalization rate [5,6]. This study revealed an increase in the number of people with eGRF-based CKD (stage1-5) in southern Taiwan from 2011 to 2013; the prevalence rates for CKD were 18.5%, 17.5%, and 22.7%, respectively. Previously reported prevalence rates of CKD in Taiwan include 9.8%, 11.9%, and 16.1%, as found in a 1999-2003 insurance data analysis [7], a study among people aged 20 or over in 1994-2006 [1], and a study on people aged 40 or over [8], respectively. These prevalence rates correspond to the findings in this study. CKD prevalence has been found to vary from country to country, with prevalence rates reaching 7.85% in India, 10.1% in Singapore, 11.9% in Thailand, 12.7% in Norway, and 11% in the US [9-11].

According to the Framingham Heart Study and four other longitudinal cohort studies, CKD can increase the mortality rate, particularly, that caused by cardiovascular diseases (including coronary artery, cerebrovascular, and peripheral vascular diseases and heart failure) [12]. Initiating risk factors for CKD in an average adult include unalterable factors (such as aging, genetic diseases, ethnic factors, and gender) and alterable factors (such as diabetes, metabolic syndrome, high BP, obesity, cardiovascular diseases, anemia, primary nephrotic syndrome, genitourinary disorders, and albuminuria) [3]. This study found that male gender, old age (≥65 years), and abnormal metabolic syndrome and its components are related to a lower eGFR, thus, increasing the risk of CKD.

CKD is currently considered a serious issue in public health [13]. Awareness of CKD risk factors is important for its prevention and cure. Risk factors can be alterable or unalterable. Age, gender [14], ethnicity, and genetic diseases are unalterable factors, while controllable factors include impaired kidney function, diabetes [15], high cholesterol, obesity [16], metabolic syndrome, smoking, high-protein diet, and anemia. Aging is a risk factor for CKD, with middle-aged and older adults being more prone to CKD. CKD risk grows with age and its prevalence is much higher among people aged 60 and over [8]. This study also noted lower eGFRs in participants aged 65 and over which was consistent each year and lower eGFRs in stages 1-5 for older participants compared to those under the age of 65.

CKD severity and stages were categorized in this study based on eGFR. Multiple linear regression analysis was employed to analyze eGFR predicting factors. The results indicated that eGFR was 17.159 ml/min/1.73m2 lower in participants aged 65 and over than in younger participants, 12.999 ml/min/1.73m2  lower in males than in females, and lower in participants with abnormal metabolic syndrome, BP, WC, or triglyceride levels. One study observed 2,858 adult patients for 8.5 years and found that age, high BP, diabetes, and low-density lipoprotein cholesterol are important factors that can cause a kidney disease [17]. Four of the main diseases related to ESRD include diabetes (43.2%), chronic glomerulonephritis (25.1%), high BP (8.3%), and chronic interstitial nephritis (2.8%), among which diabetes is the leading cause of ESRD [18]. Some studies reported that GFR decreases by 10-12 ml/min per year in diabetic patients with ESRD whose BP is not controlled; moreover, continuous high BP and albuminuria accelerate the deterioration of kidney function [19]. Dyslipidemia is another possible reason for inflammation and GFR decline [20]. CKD patients were found to have a higher risk of cardiovascular diseases than other patients. High blood cholesterol is one of main causes of atherosclerosis. One clinical study showed that dyslipidemia can cause atherosclerotic renal disease, glomerulosclerosis, and GFR decline, leading to an impaired kidney function [21]; this is consistent with the findings in this study. With regard to the lower eGFR observed in participants with abnormal WC, a past study noted an abnormally high proportion of eGFRs <60 among patients with a body mass index (BMI) ≥27 Kg/m2, and that higher BMI was found to be related to higher CKD incidence and risk of ESRD [22,23]. The results of this study were also similar.

Studies examining normal kidney function identified hyperuricemia as a risk factor for CKD [24]. Due to the recent exclusion of the uric acid test from the physical examination, this study could not analyze the effect of uric acid on CKD. However, uric acid was found to directly or indirectly damage the kidneys. An excess of uric acid is related to the risk factors of CKD, including high BP, diabetes, and cardiovascular diseases, through which it can cause deterioration of kidney function and metabolic syndrome [25]. Therefore, uric acid should be considered in future research.

The results of this study can serve as reference for local health care trends. Understanding the regional eGFR changes and influencing factors can benefit long-term health promotion and health care resource utilization.

**Limitations**

The data used in this study were collected only from one hospital; thus, the results may not be generalizable to the general population due to selection bias. However, given the large sample size, the results can still serve as a reference for other studies. Using health check data for analysis, this study did not include all the potential factors influencing CKD and, thus, has limited the inferences.

**Table 1. GFR-based CKD stages in 2011-2013 (n=9702)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | 2011 (n=1203) | 2012 (n=3391) | 2013 (n=5108) | *p* value |
| n | % | n | % | n | % |
| CKD Stage |  |  |  |  |  |  | <.001 |
| non CKD | 980 | 81.5 | 2797 | 82.5 | 3950 | 77.3 |  |
| stage1(≥90)\* | 45 | 3.7 | 98 | 2.9 | 202 | 4 |  |
| stage2(60-89) | 36 | 3 | 124 | 3.7 | 288 | 5.6 |  |
| stage3(30-59) | 127 | 10.6 | 313 | 9.2 | 577 | 11.3 |  |
| stage4(15-29) | 10 | 0.8 | 43 | 1.3 | 69 | 1.4 |  |
| stage5(<15) | 5 | 0.4 | 16 | 0.5 | 22 | 0.4 |  |

\*eGFR: ml/min/1.73m2

**Table 2. Correlation between demographic characteristics and metabolic syndrome components and GFR (n=9702)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Non CKD (n=7727)** | **stage 1 (n=345)****(**≥90**)#** | **stage 2 (n=448)****(**60-89**) #** | **stage 3 (n=1017)****(**30-59**) #** | **stage 4 (n=122)****(15-29) #** | **stage 5 (n=43)****(**<15**) #** | ***p* value** |
| **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| **Gender** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
|   Male | 3799 | 74.1 | 184 | 3.6 | 312 | 6.1 | 725 | 14.1 | 80 | 1.6 | 25 | 0.5 |  |
|   Female | 3928 | 85.8 | 161 | 3.5 | 136 | 3.0 | 292 | 6.4 | 42 | 0.9 | 18 | 0.4  |  |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
| < 65 years | 4626 | 88.1 | 232 | 4.4 | 181 | 3.4 | 169 | 3.2 | 24 | 0.5 | 16 | 0.3 |  |
|  ≥ 65 years | 3101 | 69.6 | 113 | 2.5 | 267 | 6.0 | 848 | 19.0  | 98 | 2.2 | 27 | 0.6 |  |
| **WC** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
|  Normal | 4591 | 83.5 | 185 | 3.4 | 205 | 3.7 | 450 | 8.2 | 50 | 0.9 | 19 | 0.3 |  |
| Abnormal | 3136 | 74.6 | 160 | 3.8 | 243 | 5.8 | 567 | 13.5 | 72 | 1.7 | 24 | 0.6 |  |
| **BPa** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
| Normal | 4589 | 85.0 | 179 | 3.3 | 180 | 3.3 | 380 | 7.0 | 52 | 1.0 | 16 | 0.3 |  |
| Abnormal (≥130/85) | 3138 | 72.9 | 166 | 3.9 | 268 | 6.2 | 637 | 14.8 | 70 | 1.6 | 27 | 0.6 |  |
| **Triglycerides** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
| Normal | 5790 | 81.4 | 237 | 3.3 | 295 | 4.1 | 675 | 9.5 | 84 | 1.2 | 29 | 0.4 |  |
| Abnormal (≥150mg/dL) | 1937 | 74.7 | 108 | 4.2 | 153 | 5.9 | 342 | 13.2 | 38 | 1.5 | 14 | 0.5 |  |
| **HDL** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
| Normal | 5436 | 81.6 | 213 | 3.2 | 277 | 4.2 | 639 | 9.6 | 71 | 1.1 | 22 | 0.3 |  |
| Abnormal | 2291 | 75.3 | 132 | 4.3 | 171 | 5.6 | 378 | 12.4 | 51 | 1.7 | 21 | 0.7 |  |
| **FPGb** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
| Normal | 4748 | 84.7 | 155 | 2.8 | 169 | 3.0 | 467 | 8.3 | 55 | 1.0 | 14 | 0.2 |  |
| Abnormal (≥100mg/dL) | 2979 | 72.8 | 190 | 4.6 | 279 | 6.8 | 550 | 13.4 | 67 | 1.6 | 29 | 0.7 |  |
| **Metabolic syndrome** |  |  |  |  |  |  |  |  |  |  |  |  | <.001 |
|  No (＜3 abnormal metabolic components) | 5539 | 84.2 | 204 | 3.1 | 230 | 3.5 | 528 | 8.0 | 64 | 1.0 | 17 | 0.3 |  |
|  Yes (≥3 abnormal metabolic components) | 2188 | 70.1 | 141 | 4.5 | 218 | 7.0 | 489 | 15.7 | 58 | 1.9 | 26 | 0.8 |  |

Note: Two-tailed chi-squared test; significance level α=.05.

a blood pressure of at least 130/85mmHg or taking antihypertensive medication.

b raised fasting plasma glucose (FPG) ≥100 mg/dL and/or taking anti-glycemic medication.

**#** eGFR: ml/min/1.73m2.

**Table 3. Correlation between demographic characteristics and metabolic syndrome components and eGFR (n=9702)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **eGFR**  |  |  |
| **Variable** | **N** | **Mean±SD** | ***t*** | ***P* value** |
| **Gender** |  |  | -29.34 | <.001 |
| Male | 5125 | 81.79±23.37 |  |  |
| Female | 4577 | 97.04±27.36 |  |  |
| **Age** |  |  | 39.99 | <.001 |
| < 65 years | 5248 | 98.16±24.37 |  |  |
|  ≥ 65 years | 4454 | 78.18±24.66 |  |  |
| **WC** |  |   | 10.58 | <.001 |
| Normal | 5500 | 91.47±25.93 |  |  |
| Abnormal | 4202 | 85.74±26.78 |  |  |
| **BP (mmHg)** |  |  | 16.51 | <.001 |
| Normal | 5396 | 92.91±25.77 |  |  |
| Abnormal (≥130/85mg/dL) | 4306 | 84.08±26.48 |  |  |
| **Triglycerides** |  |  | 7.65 | <.001 |
| Normal | 7110 | 90.22±26.42 |  |  |
| Abnormal (≥150mg/dL) | 2592 | 85.59±26.25 |  |  |
| **HDL** |  |   | 3.25 | .001 |
| Normal | 6658 | 89.60±25.48 |  |  |
| Abnormal | 3044 | 87.65±28.43 |  |  |
| **FPG** |  |  | 11.57 | <.001 |
| Normal | 5608 | 91.61±25.89 |  |  |
| Abnormal (≥100mg/dL) | 4094 | 85.36±26.78 |  |  |
| **Metabolic syndrome** |  |  | 13.73 | <.001 |
| No (<3 abnormal metabolic components) | 6582 | 91.56±25.67 |  |  |
| Yes (≥3 abnormal metabolic components) | 3120 | 83.57±27.25 |  |  |

**Table 4. Correlation between demographic characteristics and metabolic syndrome components and eGFR in 2011-2013**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **2011 (n=1203)** |  | **2012 (n=3391)** |  | **2013 (n=5108)** |  |
| n | *t*-value | ***p* value** |  | *t*-value | ***p* value** | n | *t*-value | ***p* value** |
| Mean±SD | n | Mean±SD | Mean±SD |
| **Gender** |  | -10.91 | <.001 |  | -19.09 | <.001 |  | -19.62 | <.001 |
| Male | 624 | 82.11±23.86 |  | 1672 | 81.06±22.59 |  | 2829 | 82.16±23.72 |  |
| Female | 579 | 98.76±28.67 |  | 1719 | 97.16±26.42 |  | 2279 | 96.52±27.71 |  |
| **Age** |  | 19.94 | <.001 |  | 23.20 | <.001 |  | 29.40  | <.001 |
| < 65 years | 672 | 99.27±25.41 |  | 1875 | 97.84±24.23 |  | 2701 | 98.11±24.21 |  |
|  ≥ 65 years | 531 | 78.56±25.80 |  | 1516 | 78.57±23.83 |  | 2407 | 77.85±24.93 |  |
| **WC** |  | 3.48 | 0.001 |  | 5.87 | <.001 |  | 8.10 | <.001 |
| Normal | 666 | 92.60±27.58 |  | 2002 | 91.41±25.03 |  | 2832 | 91.24±26.15 |  |
| Abnormal | 537 | 87.06±27.26 |  | 1389 | 86.07±26.76 |  | 2276 | 85.23±26.78 |  |
| **BP (mmHg)** |  | 5.66 | <.001 |  | 11.17 | <.001 |  | 10.90 | <.001 |
| Normal | 680 | 94.02±26.55 |  | 1948 | 93.45±23.79 |  | 2768 | 92.24±26.23 |  |
| Abnormal (≥130/85mg/dL) | 523 | 85.07±28.06 |  | 1443 | 83.51±26.34 |  | 2340 | 84.21±26.28 |  |
| **Triglycerides** |  | 1.83 | 0.068 |  | 4.06  | <.001 |  | 6.22 | <.001 |
| Normal | 907 | 90.96±27.74 |  | 2569 | 90.24±25.93 |  | 3634 | 90.03±26.43 |  |
| Abnormal (≥150mg/dL) | 296 | 87.59±26.92 |  | 822 | 86.05±25.50 |  | 1474 | 84.95±26.51 |  |
| **HDL** |  | 0.91 | 0.363 |  | 0.78 | 0.438 |  | 3.72 | <.001 |
| Normal | 645 | 90.80±26.57 |  | 2002 | 89.46±25.21 |  | 2832 | 89.48±25.45 |  |
| Abnormal | 558 | 89.35±28.67 |  | 1389 | 88.69±27.36 |  | 2276 | 86.24±29.03 |  |
| **FPG** |  | 4.32 | <.001 |  | 6.16 | <.001 |  | 8.78 | <.001 |
| Normal | 765 | 92.71±27.14 |  | 1889 | 91.65±25.72 |  | 2954 | 91.35±25.67 |  |
| Abnormal (≥100mg/dL) | 438 | 85.62±27.75 |  | 1502 | 86.17±25.77 |  | 2154 | 84.73±27.27 |  |
| **Metabolic syndrome** |  | 4.60 | <.001 |  | 8.30  | <.001 |  | 10.30 | <.001 |
| No (<3 abnormal metabolic components) | 800 | 92.75±26.72 |  | 2352 | 91.65±25.29 |  | 3430 | 91.21±26.68 |  |
| Yes (≥3 abnormal metabolic components) | 403 | 84.91±28.50 |  | 1039 | 83.73±26.38 |  | 1678 | 83.15±27.48 |  |

**Table 5. Regression Analysis of Risk Factors of GRF**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Unstandardized Coefficient β\* | Standardized Coefficient β Distribution | p-value |
|  (Constant) | 107.480 |  | <0.001 |
| Age | -17.159 | -0.323 | <0.001 |
| Gender | -12.999 | -0.245 | <0.001 |
| Metabolic syndrome | -2.100 | -0.037 | 0.005 |
| BP | -2.743 | -0.052 | <0.001 |
| WC | -2.820 | -0.053 | <0.001 |
| Triglycerides | -2.372 | -0.040 | <0.001 |

\*Reference group for analysis variables: <65 years old, female, without metabolic syndrome, normal BP, normal WC, normal triglyceride levels

**References**

[1] [C.P](http://www.ncbi.nlm.nih.gov/pubmed?term=Wen%20CP%5BAuthor%5D&cauthor=true&cauthor_uid=18586172). Wen, T.Y. [Cheng](http://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%20TY%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), M.K. [Tsai](http://www.ncbi.nlm.nih.gov/pubmed?term=Tsai%20MK%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), Y.C. [Chang](http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20YC%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), H.T. [Chan](http://www.ncbi.nlm.nih.gov/pubmed?term=Chan%20HT%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), S.P. [Tsai](http://www.ncbi.nlm.nih.gov/pubmed?term=Tsai%20SP%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), P.H. [Chiang](http://www.ncbi.nlm.nih.gov/pubmed?term=Chiang%20PH%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), C.C. [Hsu](http://www.ncbi.nlm.nih.gov/pubmed?term=Hsu%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), P.K. [Sung](http://www.ncbi.nlm.nih.gov/pubmed?term=Sung%20PK%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), Y.H. [Hsu](http://www.ncbi.nlm.nih.gov/pubmed?term=Hsu%20YH%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), S.F. [Wen](http://www.ncbi.nlm.nih.gov/pubmed?term=Wen%20SF%5BAuthor%5D&cauthor=true&cauthor_uid=18586172), All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan, [Lancet,](http://www.ncbi.nlm.nih.gov/pubmed/?term=All-cause+mortality+attributable+to+chronic+kidney+++disease%3A+a+prospective+cohort+study+based+on+462+293+adults+in+Taiwan) 371, (2008), 2173-2182.

[2] Ministry of Health and Welfare, The cause of death statistics (2014).

[3] Health Promotion Administration, Ministry of Health and Welfare. Prevention Manual of Chronic Kidney Diseases (2010).

[4] M.J. [Wu](http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), K.H. [Shu](http://www.ncbi.nlm.nih.gov/pubmed?term=Shu%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), P.H. [Liu](http://www.ncbi.nlm.nih.gov/pubmed?term=Liu%20PH%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), P.H. [Chiang](http://www.ncbi.nlm.nih.gov/pubmed?term=Chiang%20PH%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), C.H. [Cheng](http://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), C.H. [Chen](http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), D.M. [Yu](http://www.ncbi.nlm.nih.gov/pubmed?term=Yu%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), Y.W. [Chuang](http://www.ncbi.nlm.nih.gov/pubmed?term=Chuang%20YW%5BAuthor%5D&cauthor=true&cauthor_uid=21051028), High risk of renal failure in stage 3B chronic kidney disease is under-recognized in standard medical screening, [J Chin Med Assoc, 73, (](http://www.ncbi.nlm.nih.gov/pubmed/?term=High+risk+of+renal+failure+in+stage+3B+chronic+kidney++disease+is+under-recognized+in+standard+medical+screening)2010), 515-522.

[5] P. Muntmer, J. He, L. Hamm, C. Loria, P.K. Whelton, Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States, [J Am Soc Nephrol,](http://www.ncbi.nlm.nih.gov/pubmed/?term=Muntmer+P%2C+He+J%2C+Hamm+L%2C+Loria+C%2C+Whelton+PK) 13, (2002), 745-753.

[6] A.S. [Go](http://www.ncbi.nlm.nih.gov/pubmed/?term=Go%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=15385656), G.M. [Chertow](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chertow%20GM%5BAuthor%5D&cauthor=true&cauthor_uid=15385656), D. [Fan](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fan%20D%5BAuthor%5D&cauthor=true&cauthor_uid=15385656), C.E. [McCulloch](http://www.ncbi.nlm.nih.gov/pubmed/?term=McCulloch%20CE%5BAuthor%5D&cauthor=true&cauthor_uid=15385656), C.Y. [Hsu](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hsu%20CY%5BAuthor%5D&cauthor=true&cauthor_uid=15385656), Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, [N Engl J Med,](http://www.ncbi.nlm.nih.gov/pubmed/15385656) 351, (2004), 1296-1305.

[7] H.W. [Kuo](http://www.ncbi.nlm.nih.gov/pubmed?term=Kuo%20HW%5BAuthor%5D&cauthor=true&cauthor_uid=17185145), S.S. [Tsai](http://www.ncbi.nlm.nih.gov/pubmed?term=Tsai%20SS%5BAuthor%5D&cauthor=true&cauthor_uid=17185145), M.M. [Tiao](http://www.ncbi.nlm.nih.gov/pubmed?term=Tiao%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=17185145), C.Y. [Yang](http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20CY%5BAuthor%5D&cauthor=true&cauthor_uid=17185145), Epidemiological features of CKD in Taiwan, [Am J Kidney Dis,](http://www.ncbi.nlm.nih.gov/pubmed/17185145) 49, (2007), 46-55.

[8] H.W. Wu, L.C. See, R.E. Chang, W.J. Chen, M.C. Yang. Factors Associated with Chronic Kidney Disease: Analysis of Outreach Community Adult Health Examination Data, Taiwan J Public Health, 28, (2009), 374-384.

[9] S.I. [Hallan](http://www.ncbi.nlm.nih.gov/pubmed?term=Hallan%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), J. [Coresh](http://www.ncbi.nlm.nih.gov/pubmed?term=Coresh%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), B.C. [Astor](http://www.ncbi.nlm.nih.gov/pubmed?term=Astor%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), A. [Asberg](http://www.ncbi.nlm.nih.gov/pubmed?term=Asberg%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), N.R. [Powe](http://www.ncbi.nlm.nih.gov/pubmed?term=Powe%20NR%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), S. [Romundstad](http://www.ncbi.nlm.nih.gov/pubmed?term=Romundstad%20S%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), H.A. [Hallan](http://www.ncbi.nlm.nih.gov/pubmed?term=Hallan%20HA%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), S. [Lydersen](http://www.ncbi.nlm.nih.gov/pubmed?term=Lydersen%20S%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), J. [Holmen](http://www.ncbi.nlm.nih.gov/pubmed?term=Holmen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16790511), International comparison of the relationship of chronic kidney disease prevalence and ESRD risk, [J Am Soc Nephrol,](http://www.ncbi.nlm.nih.gov/pubmed/?term=International+comparison+of+the+relationship+of+chronic+kidney+disease+prevalence+and+ESRD+risk) 17, (2006), 2275-2284.

[10] S.I. [Hallan](http://www.ncbi.nlm.nih.gov/pubmed?term=Hallan%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), K. [Dahl](http://www.ncbi.nlm.nih.gov/pubmed?term=Dahl%20K%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), C.M. [Oien](http://www.ncbi.nlm.nih.gov/pubmed?term=Oien%20CM%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), D.C. [Grootendorst](http://www.ncbi.nlm.nih.gov/pubmed?term=Grootendorst%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), A. [Aasberg](http://www.ncbi.nlm.nih.gov/pubmed?term=Aasberg%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), J. [Holmen](http://www.ncbi.nlm.nih.gov/pubmed?term=Holmen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), F.W. [Dekker](http://www.ncbi.nlm.nih.gov/pubmed?term=Dekker%20FW%5BAuthor%5D&cauthor=true&cauthor_uid=17062598), Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey, [BMJ,](http://www.ncbi.nlm.nih.gov/pubmed/?term=Screening+strategies+for+chronic+kidney+disease+in+the+general+population%3A+follow-up+of+cross+sectional+health+survey) 333 (2006), 1047.

[11] I. [Sahin](http://www.ncbi.nlm.nih.gov/pubmed?term=Sahin%20I%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), B. [Yildirim](http://www.ncbi.nlm.nih.gov/pubmed?term=Yildirim%20B%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), I. [Cetin](http://www.ncbi.nlm.nih.gov/pubmed?term=Cetin%20I%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), I. [Etikan](http://www.ncbi.nlm.nih.gov/pubmed?term=Etikan%20I%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), B. [Ozturk](http://www.ncbi.nlm.nih.gov/pubmed?term=Ozturk%20B%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), H. [Ozyurt](http://www.ncbi.nlm.nih.gov/pubmed?term=Ozyurt%20H%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), T. [Tasliyurt](http://www.ncbi.nlm.nih.gov/pubmed?term=Tasliyurt%20T%5BAuthor%5D&cauthor=true&cauthor_uid=20030527), Prevalence of chronic kidney disease in the Black Sea Region, Turkey, and investigation of the related factors with chronic kidney disease, [Ren Fail,](http://www.ncbi.nlm.nih.gov/pubmed/?term=Prevalence+of+Chronic+Kidney+Disease+in+the+Black+Sea+Region%2CTurkey%2C+and+Investigation+of+the+Related+Factors+with+Chronic+Kidney+Disease) 31, (2009), 920-927.

[12] D.E. [Weiner](http://www.ncbi.nlm.nih.gov/pubmed?term=Weiner%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), H. [Tighiouart](http://www.ncbi.nlm.nih.gov/pubmed?term=Tighiouart%20H%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), M.G. [Amin](http://www.ncbi.nlm.nih.gov/pubmed?term=Amin%20MG%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), P.C. [Stark](http://www.ncbi.nlm.nih.gov/pubmed?term=Stark%20PC%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), B. [MacLeod](http://www.ncbi.nlm.nih.gov/pubmed?term=MacLeod%20B%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), J.L. [Griffith](http://www.ncbi.nlm.nih.gov/pubmed?term=Griffith%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), D.N. [Salem](http://www.ncbi.nlm.nih.gov/pubmed?term=Salem%20DN%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), A.S. [Levey](http://www.ncbi.nlm.nih.gov/pubmed?term=Levey%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), M.J. [Sarnak](http://www.ncbi.nlm.nih.gov/pubmed?term=Sarnak%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=15100371), Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies, [J Am Soc Nephrol,](http://www.ncbi.nlm.nih.gov/pubmed/15100371) 15, (2004), 1307-1315.

[13] A.S. [Levey](http://www.ncbi.nlm.nih.gov/pubmed?term=Levey%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), R. [Atkins](http://www.ncbi.nlm.nih.gov/pubmed?term=Atkins%20R%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), J. [Coresh](http://www.ncbi.nlm.nih.gov/pubmed?term=Coresh%20J%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), E.P. [Cohen](http://www.ncbi.nlm.nih.gov/pubmed?term=Cohen%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), A.J. [Collins](http://www.ncbi.nlm.nih.gov/pubmed?term=Collins%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), K.U. [Eckardt](http://www.ncbi.nlm.nih.gov/pubmed?term=Eckardt%20KU%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), M.E. [Nahas](http://www.ncbi.nlm.nih.gov/pubmed?term=Nahas%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), B.L. [Jaber](http://www.ncbi.nlm.nih.gov/pubmed?term=Jaber%20BL%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), M. [Jadoul](http://www.ncbi.nlm.nih.gov/pubmed?term=Jadoul%20M%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), A. [Levin](http://www.ncbi.nlm.nih.gov/pubmed?term=Levin%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), N.R. [Powe](http://www.ncbi.nlm.nih.gov/pubmed?term=Powe%20NR%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), J. [Rossert](http://www.ncbi.nlm.nih.gov/pubmed?term=Rossert%20J%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), D.C. [Wheeler](http://www.ncbi.nlm.nih.gov/pubmed?term=Wheeler%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), N. [Lameire](http://www.ncbi.nlm.nih.gov/pubmed?term=Lameire%20N%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), G. [Eknoyan](http://www.ncbi.nlm.nih.gov/pubmed?term=Eknoyan%20G%5BAuthor%5D&cauthor=true&cauthor_uid=17568785), Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes, [Kidney Int,](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chronic+kidney+disease+as+a+global+public+health+problem%3A+approaches+and+initiatives%E2%80%93a+position+statement+from+Kidney+Disease+Improving+Global+Outcomes) 72, (2007), 247-259.

[14] B. Eriksen, O. Ingebretsen, The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age, [Kidney Int,](http://www.ncbi.nlm.nih.gov/pubmed/?term=The+progression+of+chronic+kidney+disease%3A+a+10-year+population-based+study+of+the+effects+of+gender+and+age) 69, (2006), 375-382.

[15] D. [de Zeeuw](http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Zeeuw%20D%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), D. [Ramjit](http://www.ncbi.nlm.nih.gov/pubmed?term=Ramjit%20D%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), Z. [Zhang](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhang%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), A.B. [Ribeiro](http://www.ncbi.nlm.nih.gov/pubmed?term=Ribeiro%20AB%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), K. [Kurokawa](http://www.ncbi.nlm.nih.gov/pubmed?term=Kurokawa%20K%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), J.P. [Lash](http://www.ncbi.nlm.nih.gov/pubmed?term=Lash%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), J. [Chan](http://www.ncbi.nlm.nih.gov/pubmed?term=Chan%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), G. [Remuzzi](http://www.ncbi.nlm.nih.gov/pubmed?term=Remuzzi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), B.M. [Brenner](http://www.ncbi.nlm.nih.gov/pubmed?term=Brenner%20BM%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), S. [Shahinfar](http://www.ncbi.nlm.nih.gov/pubmed?term=Shahinfar%20S%5BAuthor%5D&cauthor=true&cauthor_uid=16572114), Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL, [Kidney Int, 69,](http://www.ncbi.nlm.nih.gov/pubmed/?term=De+Zeeuw+D%2C+Ramjit+D%2C+Zhang+Z%2C+Ribeiro+A%2C+Kurokawa+K%2C+Lash) (2006), 1675-1682.

[16] A. [Chagnac](http://www.ncbi.nlm.nih.gov/pubmed?term=Chagnac%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), T. [Weinstein](http://www.ncbi.nlm.nih.gov/pubmed?term=Weinstein%20T%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), M. [Herman](http://www.ncbi.nlm.nih.gov/pubmed?term=Herman%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), J. [Hirsh](http://www.ncbi.nlm.nih.gov/pubmed?term=Hirsh%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), U. [Gafter](http://www.ncbi.nlm.nih.gov/pubmed?term=Gafter%20U%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), Y. [Ori](http://www.ncbi.nlm.nih.gov/pubmed?term=Ori%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=12761248), The effects of weight loss on renal function in patients with severe obesity, [J Am Soc Nephrol,](http://www.ncbi.nlm.nih.gov/pubmed/12761248) 14, (2003), 1480-1486.

[17] C.S. [Fox](http://www.ncbi.nlm.nih.gov/pubmed?term=Fox%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), M.G. [Larson](http://www.ncbi.nlm.nih.gov/pubmed?term=Larson%20MG%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), E.P. [Leip](http://www.ncbi.nlm.nih.gov/pubmed?term=Leip%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), B. [Culleton](http://www.ncbi.nlm.nih.gov/pubmed?term=Culleton%20B%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), P.W. [Wilson](http://www.ncbi.nlm.nih.gov/pubmed?term=Wilson%20PW%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), D. [Levy](http://www.ncbi.nlm.nih.gov/pubmed?term=Levy%20D%5BAuthor%5D&cauthor=true&cauthor_uid=14970063), Predictors of new-onset kidney disease in a community-based population, [JAMA,](http://www.ncbi.nlm.nih.gov/pubmed/14970063) 291, (2004), 844-850.

[18] S.J. [Hwang](http://www.ncbi.nlm.nih.gov/pubmed?term=Hwang%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=20586940), J.C. [Tsai](http://www.ncbi.nlm.nih.gov/pubmed?term=Tsai%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=20586940), H.C. [Chen](http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20HC%5BAuthor%5D&cauthor=true&cauthor_uid=20586940), Epidemiology, impact and preventive care of chronic kidney disease in Taiwan, [Nephrology (Carlton),](http://www.ncbi.nlm.nih.gov/pubmed/20586940) 15 Suppl 2, (2010), 3-9.

[19] B.J. [Barrett](http://www.ncbi.nlm.nih.gov/pubmed?term=Barrett%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=12641881), Applying multiple interventions in chronic kidney disease, [Semin Dial,](http://www.ncbi.nlm.nih.gov/pubmed/12641881) 16, (2003), 157-164.

[20] M.W. [Taal](http://www.ncbi.nlm.nih.gov/pubmed?term=Taal%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=16969387), B.M. [Brenner](http://www.ncbi.nlm.nih.gov/pubmed?term=Brenner%20BM%5BAuthor%5D&cauthor=true&cauthor_uid=16969387), Predicting initiation and progression of chronic kidney disease: Developing renal risk scores, [Kidney Int,](http://www.ncbi.nlm.nih.gov/pubmed/?term=Predicting+initiation+and+progression+of++chronic+kidney+disease%3A+developing+renal+risk+scores) 70, (2006), 1694-1705.

[21] A.S. [Mühlfeld](http://www.ncbi.nlm.nih.gov/pubmed?term=M%C3%BChlfeld%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), M.W. [Spencer](http://www.ncbi.nlm.nih.gov/pubmed?term=Spencer%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), K.L. [Hudkins](http://www.ncbi.nlm.nih.gov/pubmed?term=Hudkins%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), E. [Kirk](http://www.ncbi.nlm.nih.gov/pubmed?term=Kirk%20E%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), R.C. [LeBoeuf](http://www.ncbi.nlm.nih.gov/pubmed?term=LeBoeuf%20RC%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), C.E. [Alpers](http://www.ncbi.nlm.nih.gov/pubmed?term=Alpers%20CE%5BAuthor%5D&cauthor=true&cauthor_uid=15458432), Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice, [Kidney Int,](http://www.ncbi.nlm.nih.gov/pubmed/15458432) 66, (2004), 1393-1402.

[22] A. Shankar, C. Leng, K.S. Chia, D. Koh, E.S. Tai, S.M. Saw, S.C. Lim, T.Y. Wong, Association between body mass index and chronic kidney disease in men and women: population-based study of Malay adults in Singapore, Nephrology Dialysis Transplantation, 23, (2008), 1910-1918.

[23] C. Hsu, C.E. McCulloch, C. Iribarren, J. Darbinian, A.S. Go, Body mass index and risk for end-stage renal disease, Annals of internal medicine,144, (2006), 21-28.

[24] D.E. Weiner, H. Tighiouart, E.F. Elsayed, J.L. Griffith, D.N. Salem, A.S. Levey, Uric acid and incident kidney disease in the community, Journal of the American Society of Nephrology, 19, (2008), 1204.

[25] D.I. [Feig](http://www.ncbi.nlm.nih.gov/pubmed?term=Feig%20DI%5BAuthor%5D&cauthor=true&cauthor_uid=18946066), D.H. [Kang](http://www.ncbi.nlm.nih.gov/pubmed?term=Kang%20DH%5BAuthor%5D&cauthor=true&cauthor_uid=18946066), R.J. [Johnson](http://www.ncbi.nlm.nih.gov/pubmed?term=Johnson%20RJ%5BAuthor%5D&cauthor=true&cauthor_uid=18946066), Uric acid and cardiovascular risk, [N Engl J Med,](http://www.ncbi.nlm.nih.gov/pubmed/18946066) 359, (2008), 1811-1821.